Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08-28

AUTHORS

Toussaint Rouamba, Innocent Valea, Joel D. Bognini, Herve Kpoda, Petra F. Mens, Melba F. Gomes, Halidou Tinto, Fati Kirakoya-Samadoulougou

ABSTRACT

PURPOSE: Safety data of many drugs used during pregnancy remain scarce. This is especially true in developing countries characterised by the absence of a robust pharmacovigilance system, high prevalence of different tropical diseases affecting patients and potential for drug-drug interactions. This study aimed to assess the safety profile of drugs used in women at high risk of malaria during pregnancy and delivery in Burkina Faso's health facilities. It also aimed to assess factors associated with the use of potentially risky drugs over the entire course of pregnancy. METHODS: We enrolled pregnant women from their first antenatal care visit and followed them up until delivery, and collected data on drug use. Based on United States Food and Drug Administration (FDA) or Australian Therapeutic Goods Administration (TGA) drug risk classification, drugs were classified into three groups: 'probably safe', 'potentially risky' or 'unclassified'. A modified classification was built to take into account national malaria policy treatment guidelines and World Health Organization Malaria Treatment Guidelines recommending malaria chemoprophylaxis during pregnancy. RESULTS: Out of 2371 pregnant women enrolled, 56.7% used at least one medication during the entire course of the pregnancy (excluding sulphadoxine-pyrimethamine and iron-folic acid). A total of 101 different types of medications were used by study participants and 36.6, 49.5 and 13.9% were, respectively, classified as 'probably safe', 'potentially risky' and 'unclassified'. Antimalarials and antibiotics were the most frequently used drugs. Around 39% of women used a least one medication classified as potentially risky. However, this proportion dropped to 26% with the modified classification. Living in urban areas and attending the first antenatal care within their first trimester of pregnancy (longer health surveillance) were associated with using 'potentially risky' medications. CONCLUSION: This study provides rare and valuable information on the current use of drugs among pregnant women in Burkina Faso. Many pregnant women used medications classified as potentially risky. Our findings suggest the need for rational drug prescription and community education to reduce hazardous drug exposure during pregnancy. More... »

PAGES

193-206

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0141-1

DOI

http://dx.doi.org/10.1007/s40801-018-0141-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106391076

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30155832


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso", 
          "id": "http://www.grid.ac/institutes/grid.457337.1", 
          "name": [
            "Centre de Recherche en Epid\u00e9miologie, Biostatistique et Recherche Clinique, Ecole de Sant\u00e9 Publique, Universit\u00e9 libre de Bruxelles, Brussels, Belgium", 
            "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rouamba", 
        "givenName": "Toussaint", 
        "id": "sg:person.014513645713.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014513645713.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso", 
          "id": "http://www.grid.ac/institutes/grid.457337.1", 
          "name": [
            "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valea", 
        "givenName": "Innocent", 
        "id": "sg:person.0610262076.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610262076.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso", 
          "id": "http://www.grid.ac/institutes/grid.457337.1", 
          "name": [
            "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bognini", 
        "givenName": "Joel D.", 
        "id": "sg:person.010536360356.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010536360356.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Muraz, D\u00e9partement de Recherche Clinique, Bobo-Dioulasso, Burkina Faso", 
          "id": "http://www.grid.ac/institutes/grid.418128.6", 
          "name": [
            "Centre Muraz, D\u00e9partement de Recherche Clinique, Bobo-Dioulasso, Burkina Faso"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kpoda", 
        "givenName": "Herve", 
        "id": "sg:person.0700014730.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700014730.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.5650.6", 
          "name": [
            "Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mens", 
        "givenName": "Petra F.", 
        "id": "sg:person.01247352713.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247352713.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.3575.4", 
          "name": [
            "World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gomes", 
        "givenName": "Melba F.", 
        "id": "sg:person.01346334651.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346334651.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso", 
          "id": "http://www.grid.ac/institutes/grid.457337.1", 
          "name": [
            "Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Sant\u00e9, Unit\u00e9 de Recherche Clinique de Nanoro, Nanoro, Burkina Faso"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tinto", 
        "givenName": "Halidou", 
        "id": "sg:person.01056515430.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056515430.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre de Recherche en Epid\u00e9miologie, Biostatistique et Recherche Clinique, Ecole de Sant\u00e9 Publique, Universit\u00e9 libre de Bruxelles, Brussels, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.4989.c", 
          "name": [
            "Centre de Recherche en Epid\u00e9miologie, Biostatistique et Recherche Clinique, Ecole de Sant\u00e9 Publique, Universit\u00e9 libre de Bruxelles, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirakoya-Samadoulougou", 
        "givenName": "Fati", 
        "id": "sg:person.01353376401.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353376401.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12978-015-0101-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050771232", 
          "https://doi.org/10.1186/s12978-015-0101-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2393-8-24", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049860144", 
          "https://doi.org/10.1186/1471-2393-8-24"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13033-016-0070-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052993629", 
          "https://doi.org/10.1186/s13033-016-0070-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12884-017-1359-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085865405", 
          "https://doi.org/10.1186/s12884-017-1359-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2393-14-322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020173114", 
          "https://doi.org/10.1186/1471-2393-14-322"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2875-7-95", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030349950", 
          "https://doi.org/10.1186/1475-2875-7-95"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-540-79116-4_21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008969833", 
          "https://doi.org/10.1007/978-3-540-79116-4_21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11591270-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035847405", 
          "https://doi.org/10.2165/11591270-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200427060-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039943798", 
          "https://doi.org/10.2165/00002018-200427060-00001"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08-28", 
    "datePublishedReg": "2018-08-28", 
    "description": "PURPOSE: Safety data of many drugs used during pregnancy remain scarce. This is especially true in developing countries characterised by the absence of a robust pharmacovigilance system, high prevalence of different tropical diseases affecting patients and potential for drug-drug interactions. This study aimed to assess the safety profile of drugs used in women at high risk of malaria during pregnancy and delivery in Burkina Faso's health facilities. It also aimed to assess factors associated with the use of potentially risky drugs over the entire course of pregnancy.\nMETHODS: We enrolled pregnant women from their first antenatal care visit and followed them up until delivery, and collected data on drug use. Based on United States Food and Drug Administration (FDA) or Australian Therapeutic Goods Administration (TGA) drug risk classification, drugs were classified into three groups: 'probably safe', 'potentially risky' or 'unclassified'. A modified classification was built to take into account national malaria policy treatment guidelines and World Health Organization Malaria Treatment Guidelines recommending malaria chemoprophylaxis during pregnancy.\nRESULTS: Out of 2371 pregnant women enrolled, 56.7% used at least one medication during the entire course of the pregnancy (excluding sulphadoxine-pyrimethamine and iron-folic acid). A total of 101 different types of medications were used by study participants and 36.6, 49.5 and 13.9% were, respectively, classified as 'probably safe', 'potentially risky' and 'unclassified'. Antimalarials and antibiotics were the most frequently used drugs. Around 39% of women used a least one medication classified as potentially risky. However, this proportion dropped to 26% with the modified classification. Living in urban areas and attending the first antenatal care within their first trimester of pregnancy (longer health surveillance) were associated with using 'potentially risky' medications.\nCONCLUSION: This study provides rare and valuable information on the current use of drugs among pregnant women in Burkina Faso. Many pregnant women used medications classified as potentially risky. Our findings suggest the need for rational drug prescription and community education to reduce hazardous drug exposure during pregnancy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0141-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "pregnant women", 
      "treatment guidelines", 
      "safety profile", 
      "health facilities", 
      "drug use", 
      "first antenatal care visit", 
      "prospective observational cohort study", 
      "different tropical diseases", 
      "first antenatal care", 
      "hazardous drug exposure", 
      "observational cohort study", 
      "antenatal care visits", 
      "modified classification", 
      "malaria treatment guidelines", 
      "peripheral health centres", 
      "rational drug prescription", 
      "drug-drug interactions", 
      "United States Food", 
      "entire course", 
      "malaria chemoprophylaxis", 
      "care visits", 
      "antenatal care", 
      "cohort study", 
      "first trimester", 
      "drug prescriptions", 
      "drug exposure", 
      "high prevalence", 
      "health centers", 
      "safety data", 
      "high risk", 
      "pregnancy", 
      "medications", 
      "risky drugs", 
      "Drug Administration", 
      "robust pharmacovigilance system", 
      "pharmacovigilance system", 
      "study participants", 
      "tropical diseases", 
      "States Food", 
      "risk classification", 
      "women", 
      "drugs", 
      "Burkina Faso", 
      "current use", 
      "community education", 
      "guidelines", 
      "delivery", 
      "chemoprophylaxis", 
      "trimester", 
      "patients", 
      "malaria", 
      "prevalence", 
      "disease", 
      "antimalarials", 
      "administration", 
      "visits", 
      "course", 
      "study", 
      "care", 
      "antibiotics", 
      "prescription", 
      "risk", 
      "total", 
      "Faso", 
      "exposure", 
      "use", 
      "participants", 
      "group", 
      "profile", 
      "findings", 
      "proportion", 
      "classification", 
      "food", 
      "data", 
      "absence", 
      "factors", 
      "valuable information", 
      "center", 
      "different types", 
      "urban areas", 
      "need", 
      "education", 
      "facilities", 
      "types", 
      "countries", 
      "potential", 
      "area", 
      "information", 
      "interaction", 
      "system", 
      "Burkina Faso's health facilities", 
      "Faso's health facilities", 
      "Australian Therapeutic Goods Administration (TGA) drug risk classification", 
      "Therapeutic Goods Administration (TGA) drug risk classification", 
      "Goods Administration (TGA) drug risk classification", 
      "Administration (TGA) drug risk classification", 
      "drug risk classification", 
      "account national malaria policy treatment guidelines", 
      "national malaria policy treatment guidelines", 
      "malaria policy treatment guidelines", 
      "policy treatment guidelines", 
      "World Health Organization Malaria Treatment Guidelines", 
      "Health Organization Malaria Treatment Guidelines", 
      "Organization Malaria Treatment Guidelines"
    ], 
    "name": "Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study", 
    "pagination": "193-206", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106391076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0141-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30155832"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0141-1", 
      "https://app.dimensions.ai/details/publication/pub.1106391076"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_786.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0141-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0141-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0141-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0141-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0141-1'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      22 PREDICATES      139 URIs      122 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0141-1 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N97ae1e336db44d41b60cf2796528083d
4 schema:citation sg:pub.10.1007/978-3-540-79116-4_21
5 sg:pub.10.1186/1471-2393-14-322
6 sg:pub.10.1186/1471-2393-8-24
7 sg:pub.10.1186/1475-2875-7-95
8 sg:pub.10.1186/s12884-017-1359-8
9 sg:pub.10.1186/s12978-015-0101-0
10 sg:pub.10.1186/s13033-016-0070-x
11 sg:pub.10.2165/00002018-200427060-00001
12 sg:pub.10.2165/11591270-000000000-00000
13 schema:datePublished 2018-08-28
14 schema:datePublishedReg 2018-08-28
15 schema:description PURPOSE: Safety data of many drugs used during pregnancy remain scarce. This is especially true in developing countries characterised by the absence of a robust pharmacovigilance system, high prevalence of different tropical diseases affecting patients and potential for drug-drug interactions. This study aimed to assess the safety profile of drugs used in women at high risk of malaria during pregnancy and delivery in Burkina Faso's health facilities. It also aimed to assess factors associated with the use of potentially risky drugs over the entire course of pregnancy. METHODS: We enrolled pregnant women from their first antenatal care visit and followed them up until delivery, and collected data on drug use. Based on United States Food and Drug Administration (FDA) or Australian Therapeutic Goods Administration (TGA) drug risk classification, drugs were classified into three groups: 'probably safe', 'potentially risky' or 'unclassified'. A modified classification was built to take into account national malaria policy treatment guidelines and World Health Organization Malaria Treatment Guidelines recommending malaria chemoprophylaxis during pregnancy. RESULTS: Out of 2371 pregnant women enrolled, 56.7% used at least one medication during the entire course of the pregnancy (excluding sulphadoxine-pyrimethamine and iron-folic acid). A total of 101 different types of medications were used by study participants and 36.6, 49.5 and 13.9% were, respectively, classified as 'probably safe', 'potentially risky' and 'unclassified'. Antimalarials and antibiotics were the most frequently used drugs. Around 39% of women used a least one medication classified as potentially risky. However, this proportion dropped to 26% with the modified classification. Living in urban areas and attending the first antenatal care within their first trimester of pregnancy (longer health surveillance) were associated with using 'potentially risky' medications. CONCLUSION: This study provides rare and valuable information on the current use of drugs among pregnant women in Burkina Faso. Many pregnant women used medications classified as potentially risky. Our findings suggest the need for rational drug prescription and community education to reduce hazardous drug exposure during pregnancy.
16 schema:genre article
17 schema:inLanguage en
18 schema:isAccessibleForFree true
19 schema:isPartOf N09d557032012461d9fb8efc3d74d55ca
20 N22e4375b5eef47eda1e7e59e011211ba
21 sg:journal.1051855
22 schema:keywords Administration (TGA) drug risk classification
23 Australian Therapeutic Goods Administration (TGA) drug risk classification
24 Burkina Faso
25 Burkina Faso's health facilities
26 Drug Administration
27 Faso
28 Faso's health facilities
29 Goods Administration (TGA) drug risk classification
30 Health Organization Malaria Treatment Guidelines
31 Organization Malaria Treatment Guidelines
32 States Food
33 Therapeutic Goods Administration (TGA) drug risk classification
34 United States Food
35 World Health Organization Malaria Treatment Guidelines
36 absence
37 account national malaria policy treatment guidelines
38 administration
39 antenatal care
40 antenatal care visits
41 antibiotics
42 antimalarials
43 area
44 care
45 care visits
46 center
47 chemoprophylaxis
48 classification
49 cohort study
50 community education
51 countries
52 course
53 current use
54 data
55 delivery
56 different tropical diseases
57 different types
58 disease
59 drug exposure
60 drug prescriptions
61 drug risk classification
62 drug use
63 drug-drug interactions
64 drugs
65 education
66 entire course
67 exposure
68 facilities
69 factors
70 findings
71 first antenatal care
72 first antenatal care visit
73 first trimester
74 food
75 group
76 guidelines
77 hazardous drug exposure
78 health centers
79 health facilities
80 high prevalence
81 high risk
82 information
83 interaction
84 malaria
85 malaria chemoprophylaxis
86 malaria policy treatment guidelines
87 malaria treatment guidelines
88 medications
89 modified classification
90 national malaria policy treatment guidelines
91 need
92 observational cohort study
93 participants
94 patients
95 peripheral health centres
96 pharmacovigilance system
97 policy treatment guidelines
98 potential
99 pregnancy
100 pregnant women
101 prescription
102 prevalence
103 profile
104 proportion
105 prospective observational cohort study
106 rational drug prescription
107 risk
108 risk classification
109 risky drugs
110 robust pharmacovigilance system
111 safety data
112 safety profile
113 study
114 study participants
115 system
116 total
117 treatment guidelines
118 trimester
119 tropical diseases
120 types
121 urban areas
122 use
123 valuable information
124 visits
125 women
126 schema:name Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study
127 schema:pagination 193-206
128 schema:productId N2f8bc281322a4c5a99fa6887333db6c8
129 N4dfc749f97a548b498e04198451532b1
130 Nfeed076c6fec42cabc1e83ca50b4d80a
131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106391076
132 https://doi.org/10.1007/s40801-018-0141-1
133 schema:sdDatePublished 2021-12-01T19:41
134 schema:sdLicense https://scigraph.springernature.com/explorer/license/
135 schema:sdPublisher N112198feb6214bd7b62ade600d5aef34
136 schema:url https://doi.org/10.1007/s40801-018-0141-1
137 sgo:license sg:explorer/license/
138 sgo:sdDataset articles
139 rdf:type schema:ScholarlyArticle
140 N09d557032012461d9fb8efc3d74d55ca schema:issueNumber 3
141 rdf:type schema:PublicationIssue
142 N112198feb6214bd7b62ade600d5aef34 schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 N22e4375b5eef47eda1e7e59e011211ba schema:volumeNumber 5
145 rdf:type schema:PublicationVolume
146 N2f8bc281322a4c5a99fa6887333db6c8 schema:name doi
147 schema:value 10.1007/s40801-018-0141-1
148 rdf:type schema:PropertyValue
149 N4dfc749f97a548b498e04198451532b1 schema:name pubmed_id
150 schema:value 30155832
151 rdf:type schema:PropertyValue
152 N5b74eb458c56449cbb78c502fc483646 rdf:first sg:person.01056515430.59
153 rdf:rest N630aaa0bebca41708a6774ef9bb3ec9c
154 N630aaa0bebca41708a6774ef9bb3ec9c rdf:first sg:person.01353376401.82
155 rdf:rest rdf:nil
156 N77d472bfbcdd458488e199eaa51cfb0a rdf:first sg:person.010536360356.17
157 rdf:rest Na161431c88b044759e1df753386b9d8b
158 N7ca064607ca048618fe69f682549098f rdf:first sg:person.0610262076.25
159 rdf:rest N77d472bfbcdd458488e199eaa51cfb0a
160 N97ae1e336db44d41b60cf2796528083d rdf:first sg:person.014513645713.86
161 rdf:rest N7ca064607ca048618fe69f682549098f
162 Na161431c88b044759e1df753386b9d8b rdf:first sg:person.0700014730.90
163 rdf:rest Ne1d3d33f6a6d4fc8ae8473bbadaae558
164 Nc94b199925ae4600b6976bb81a85a9a8 rdf:first sg:person.01346334651.29
165 rdf:rest N5b74eb458c56449cbb78c502fc483646
166 Ne1d3d33f6a6d4fc8ae8473bbadaae558 rdf:first sg:person.01247352713.76
167 rdf:rest Nc94b199925ae4600b6976bb81a85a9a8
168 Nfeed076c6fec42cabc1e83ca50b4d80a schema:name dimensions_id
169 schema:value pub.1106391076
170 rdf:type schema:PropertyValue
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
175 schema:name Public Health and Health Services
176 rdf:type schema:DefinedTerm
177 sg:journal.1051855 schema:issn 2198-9788
178 2199-1154
179 schema:name Drugs - Real World Outcomes
180 schema:publisher Springer Nature
181 rdf:type schema:Periodical
182 sg:person.010536360356.17 schema:affiliation grid-institutes:grid.457337.1
183 schema:familyName Bognini
184 schema:givenName Joel D.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010536360356.17
186 rdf:type schema:Person
187 sg:person.01056515430.59 schema:affiliation grid-institutes:grid.457337.1
188 schema:familyName Tinto
189 schema:givenName Halidou
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056515430.59
191 rdf:type schema:Person
192 sg:person.01247352713.76 schema:affiliation grid-institutes:grid.5650.6
193 schema:familyName Mens
194 schema:givenName Petra F.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247352713.76
196 rdf:type schema:Person
197 sg:person.01346334651.29 schema:affiliation grid-institutes:grid.3575.4
198 schema:familyName Gomes
199 schema:givenName Melba F.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346334651.29
201 rdf:type schema:Person
202 sg:person.01353376401.82 schema:affiliation grid-institutes:grid.4989.c
203 schema:familyName Kirakoya-Samadoulougou
204 schema:givenName Fati
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353376401.82
206 rdf:type schema:Person
207 sg:person.014513645713.86 schema:affiliation grid-institutes:grid.457337.1
208 schema:familyName Rouamba
209 schema:givenName Toussaint
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014513645713.86
211 rdf:type schema:Person
212 sg:person.0610262076.25 schema:affiliation grid-institutes:grid.457337.1
213 schema:familyName Valea
214 schema:givenName Innocent
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610262076.25
216 rdf:type schema:Person
217 sg:person.0700014730.90 schema:affiliation grid-institutes:grid.418128.6
218 schema:familyName Kpoda
219 schema:givenName Herve
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700014730.90
221 rdf:type schema:Person
222 sg:pub.10.1007/978-3-540-79116-4_21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008969833
223 https://doi.org/10.1007/978-3-540-79116-4_21
224 rdf:type schema:CreativeWork
225 sg:pub.10.1186/1471-2393-14-322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020173114
226 https://doi.org/10.1186/1471-2393-14-322
227 rdf:type schema:CreativeWork
228 sg:pub.10.1186/1471-2393-8-24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049860144
229 https://doi.org/10.1186/1471-2393-8-24
230 rdf:type schema:CreativeWork
231 sg:pub.10.1186/1475-2875-7-95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030349950
232 https://doi.org/10.1186/1475-2875-7-95
233 rdf:type schema:CreativeWork
234 sg:pub.10.1186/s12884-017-1359-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085865405
235 https://doi.org/10.1186/s12884-017-1359-8
236 rdf:type schema:CreativeWork
237 sg:pub.10.1186/s12978-015-0101-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050771232
238 https://doi.org/10.1186/s12978-015-0101-0
239 rdf:type schema:CreativeWork
240 sg:pub.10.1186/s13033-016-0070-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052993629
241 https://doi.org/10.1186/s13033-016-0070-x
242 rdf:type schema:CreativeWork
243 sg:pub.10.2165/00002018-200427060-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039943798
244 https://doi.org/10.2165/00002018-200427060-00001
245 rdf:type schema:CreativeWork
246 sg:pub.10.2165/11591270-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035847405
247 https://doi.org/10.2165/11591270-000000000-00000
248 rdf:type schema:CreativeWork
249 grid-institutes:grid.3575.4 schema:alternateName World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland
250 schema:name World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland
251 rdf:type schema:Organization
252 grid-institutes:grid.418128.6 schema:alternateName Centre Muraz, Département de Recherche Clinique, Bobo-Dioulasso, Burkina Faso
253 schema:name Centre Muraz, Département de Recherche Clinique, Bobo-Dioulasso, Burkina Faso
254 rdf:type schema:Organization
255 grid-institutes:grid.457337.1 schema:alternateName Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Santé, Unité de Recherche Clinique de Nanoro, Nanoro, Burkina Faso
256 schema:name Centre National de la Recherche Scientifique et de la Technologie, Institut de Recherche en Science de la Santé, Unité de Recherche Clinique de Nanoro, Nanoro, Burkina Faso
257 Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université libre de Bruxelles, Brussels, Belgium
258 rdf:type schema:Organization
259 grid-institutes:grid.4989.c schema:alternateName Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université libre de Bruxelles, Brussels, Belgium
260 schema:name Centre de Recherche en Epidémiologie, Biostatistique et Recherche Clinique, Ecole de Santé Publique, Université libre de Bruxelles, Brussels, Belgium
261 rdf:type schema:Organization
262 grid-institutes:grid.5650.6 schema:alternateName Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
263 schema:name Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...